Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow MoonLake Immunotherapeutics

Get SEC filing alerts via email and in your feed for MoonLake Immunotherapeutics

MLTX

MoonLake Immunotherapeutics

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a biotech company focused on developing Nanobody-based therapies for inflammatory skin and joint diseases. Its lead product, SLK, targets IL-17A and IL-17F to treat conditions like hidradenitis suppurativa, psoriatic arthritis, and psoriasis. The company advances clinical trials, seeks regulatory approval, and aims for commercialization, leveraging proprietary technology, strategic licensing, and partnerships to address unmet medical needs in immunology.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from MoonLake Immunotherapeutics

1
1
MoonLake Immunotherapeutics MoonLake Immunotherapeutics Reports $69.7 Million Net Loss in Q1 2026

Via official filing (AI summary) | 25 days ago | 0 comments

2
1
MoonLake Immunotherapeutics MoonLake Immunotherapeutics Reports $230.3M Net Loss and R&D Expense Increase in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
MoonLake Immunotherapeutics MoonLake Immunotherapeutics Reports $70.7 Million Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
MoonLake Immunotherapeutics MoonLake Immunotherapeutics Reports $56.1 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
MoonLake Immunotherapeutics MoonLake Immunotherapeutics Reports $40.6 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
MoonLake Immunotherapeutics MoonLake Immunotherapeutics Reports $121.2 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
MoonLake Immunotherapeutics MoonLake Immunotherapeutics Reports Significant Financial Developments, Net Loss Increases 210.8% in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments